Patent Grant
11951215
Biologic macromolecule drug compounds are typically composed of one or more oligomeric or polymeric chains, forming a three-dimensional structure held together by non-covalent forces. While these drug compounds have the potential for a multitude of therapeutic benefits, it has been traditionally difficult to controllably deliver these compounds over a sustained period of time. Many implantable delivery devices, for example, are formed by solubilizing a drug compound into a matrix polymer. These solubilized drug molecules can diffuse through the implant and be released into a patient. Unfortunately, however, drug elution is highly dependent upon the diffusion coefficient of the drug molecule, which in turn, is inversely proportional to the molecular weight of the drug molecule. Thus, macromolecular drug compounds tend to have a lower diffusion coefficient due to their larger molecular weight. Further, such compounds often have chain length entanglements, which can even further reduce the effective diffusion coefficient. In light of these difficulties, a need continues to exist for an implantable delivery device that is capable of delivering a macromolecular compound in effective amounts over a sustained period of time.
In accordance with one embodiment of the present invention, an implantable device for delivery of a macromolecular drug compound is disclosed. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer.
Other features and aspects of the present invention are set forth in greater detail below.
A full and enabling disclosure of the present invention, including the best mode thereof, directed to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, which makes reference to the appended drawings in which:
Repeat use of references characters in the present specification and drawing is intended to represent same or analogous features or elements of the invention.
It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention.
Generally speaking, the present invention is directed to an implantable device that is capable of delivering a macromolecular drug compound for prohibiting and/or treating a condition, disease, and/or cosmetic state in a patient (e.g., human, pet, farm animal, race horse, etc.). The implantable device may have a variety of different geometric shapes, such as cylindrical (rod), disc, ring, doughnut, helical, elliptical, triangular, ovular, etc. In one embodiment, for example, the device may have a generally circular cross-sectional shape so that the overall structure is in the form of a cylinder (rod) or disc. In such embodiments, the device will typically have a diameter of from about 0.5 to about 50 millimeters, in some embodiments from about 1 to about 40 millimeters, and in some embodiments, from about 5 to about 30 millimeters. The length of the device may vary, but is typically in the range of from about 1 to about 25 millimeters. Cylindrical devices may, for instance, have a length of from about 5 to about 50 millimeters, while disc-shaped devices may have a length of from about 0.5 to about 5 millimeters.
Regardless of the particular shape or size, the device is multilayered in that it contains at least one membrane layer positioned adjacent to an outer surface of a core. The core contains a core polymer matrix that includes a hydrophobic polymer and a macromolecular drug compound that is dispersed within the core polymer matrix. Typically, macromolecular drug compounds will constitute from about 5 wt. % to about 60 wt. %, in some embodiments from about 10 wt. % to about 50 wt. %, and in some embodiments, from about 15 wt. % to about 45 wt. % of the core, while the core polymer matrix constitutes from about 40 wt. % to about 95 wt. %, in some embodiments from about 50 wt. % to about 90 wt. %, and in some embodiments, from about 55 wt. % to about 85 wt. % of the core. The membrane layer(s) also contain a polymer matrix within which a drug compound may optionally be dispersed. Notably, the concentration (wt. %) of the drug compound in the core polymer matrix is greater than the concentration (wt. %) of the drug compound in the membrane layer. In certain embodiments, for example, the membrane layer may be generally free of such a drug compound. Of course, in other embodiments, the membrane layer may contain the drug compound such that the ratio of the drug compound concentration in the core to the drug compound concentration in the membrane layer is greater than 1, in some embodiments about 1.5 or more, and in some embodiments, from about 1.8 to about 4.
Through selective control over the particular nature of the core and membrane layer(s) as noted above, and the manner in which they are formed, the present inventors have discovered that the resulting device can be effective for sustained release over a macromolecular drug compound over a prolonged period of time. For example, the implantable device can release the drug compound for a time period of about 5 days or more, in some embodiments about 10 days or more, in some embodiments from about 20 days to about 60 days, and in some embodiments, from about 25 days to about 50 days (e.g., about 30 days). Further, the present inventors have also discovered that the drug compound can be released in a controlled manner (e.g., zero order or near zero order) over the course of the release time period. After a time period of 15 days, for example, the cumulative release ratio of the implantable device may be from about 20% to about 70%, in some embodiments from about 30% to about 65%, and in some embodiments, from about 40% to about 60%. Likewise, after a time period of 30 days, the cumulative release ratio of the implantable device may still be from about 40% to about 85%, in some embodiments from about 50% to about 80%, and in some embodiments, from about 60% to about 80%. The “cumulative release ratio” may be determined by dividing the amount of the drug compound released at a particulate time interval by the total amount of drug compound initially present, and then multiplying this number by 100.
Of course, the actual dosage level of the drug compound delivered will vary depending on the particular drug compound employed and the time period for which it is intend to be released. The dosage level is generally high enough to provide a therapeutically effective amount of the drug compound to render a desired therapeutic outcome, i.e., a level or amount effective to reduce or alleviate symptoms of the condition for which it is administered. The exact amount necessary will vary, depending on the subject being treated, the age and general condition of the subject to which the macromolecular drug compound is to be delivered, the capacity of the subject's immune system, the degree of effect desired, the severity of the condition being treated, the particular macromolecular drug compound selected and mode of administration of the composition, among other factors. An appropriate effective amount can be readily determined by one of skill in the art. For example, an effective amount will typically range from about 5 μg to about 200 mg, in some embodiments from about 5μg to about 100 mg per day, and in some embodiments, from about 10 μg to about 1 mg of the macromolecular drug compound delivered per day.
Various embodiments of the present invention will now be described in more detail.
As indicated above, the core polymer matrix contains at least polymer that is generally hydrophobic in nature so that it can retain its structural integrity for a certain period of time when placed in an aqueous environment, such as the body of a mammal, and stable enough to be stored for an extended period before use. Examples of suitable hydrophobic polymers for this purpose may include, for instance, silicone polymer, polyolefins, polyvinyl chloride, polycarbonates, polysulphones, styrene acrylonitrile copolymers, polyurethanes, silicone polyether-urethanes, polycarbonate-urethanes, silicone polycarbonate-urethanes, etc., as well as combinations thereof. Of course, hydrophilic polymers that are coated or otherwise encapsulated with a hydrophobic polymer are also suitable for use in the core polymer matrix. Typically, the melt flow index of the hydrophobic polymer ranges from about 0.2 to about 100 g/10 min, in some embodiments from about 5 to about 90 g/10 min, in some embodiments from about 10 to about 80 g/10 min, and in some embodiments, from about 30 to about 70 g/10 min, as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.
In certain embodiments, the core polymer matrix may contain a semi-crystalline olefin copolymer. The melting temperature of such an olefin copolymer may, for instance, range from about 40° C. to about 140° C., in some embodiments from about 50° C. to about 125° C., and in some embodiments, from about 60° C. to about 120° C., as determined in accordance with ASTM D3418-15. Such copolymers are generally derived from at least one olefin monomer (e.g., ethylene, propylene, etc.) and at least one polar monomer that is grafted onto the polymer backbone and/or incorporated as a constituent of the polymer (e.g., block or random copolymers). Suitable polar monomers include, for instance, a vinyl acetate, vinyl alcohol, maleic anhydride, maleic acid, (meth)acrylic acid (e.g., acrylic acid, methacrylic acid, etc.), (meth)acrylate (e.g., acrylate, methacrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, etc.), and so forth. A wide variety of such copolymers may generally be employed in the polymer composition, such as ethylene vinyl acetate copolymers, ethylene (meth)acrylic acid polymers (e.g., ethylene acrylic acid copolymers and partially neutralized ionomers of these copolymers, ethylene methacrylic acid copolymers and partially neutralized ionomers of these copolymers, etc.), ethylene (meth)acrylate polymers (e.g., ethylene methylacrylate copolymers, ethylene ethyl acrylate copolymers, ethylene butyl acrylate copolymers, etc.), and so forth. Regardless of the particular monomers selected, the present inventors have discovered that certain aspects of the copolymer can be selectively controlled to help achieve the desired release properties. For instance, the polar monomeric content of the copolymer may be selectively controlled to be within a range of from about 10 wt. % to about 60 wt. %, in some embodiments about 20 wt. % to about 55 wt. %, and in some embodiments, from about 25 wt. % to about 50 wt. %. Conversely, the olefin monomeric content of the copolymer may be likewise be within a range of from about 40 wt. % to about 90 wt. %, in some embodiments about 45 wt. % to about 80 wt. %, and in some embodiments, from about 50 wt. % to about 75 wt. %.
In one particular embodiment, for example, the core polymer matrix may contain an ethylene vinyl acetate polymer, which is a copolymer that is derived from at least one ethylene monomer and at least one vinyl acetate monomer. The density of the ethylene vinyl acetate copolymer may also range from about 0.900 to about 1.00 gram per cubic centimeter (g/cm3), in some embodiments from about 0.910 to about 0.980 g/cm3, and in some embodiments, from about 0.940 to about 0.970 g/cm3, as determined in accordance with ASTM D1505-10. Examples of suitable ethylene vinyl acetate copolymers that may be employed include those available from Celanese under the designation ATEVA® (e.g., ATEVA® 4030AC); DuPont under the designation ELVAX® (e.g., ELVAX® 40W); and Arkema under the designation EVATANE® (e.g., EVATANE 40-55). Any of a variety of techniques may generally be used to form the ethylene vinyl acetate copolymer with the desired properties as is known in the art. In one embodiment, the polymer is produced by copolymerizing an ethylene monomer and a vinyl acetate monomer in a high pressure reaction. Vinyl acetate may be produced from the oxidation of butane to yield acetic anhydride and acetaldehyde, which can react together to form ethylidene diacetate. Ethylidene diacetate can then be thermally decomposed in the presence of an acid catalyst to form the vinyl acetate monomer. Examples of suitable acid catalysts include aromatic sulfonic acids (e.g., benzene sulfonic acid, toluene sulfonic acid, ethylbenzene sulfonic acid, xylene sulfonic acid, and naphthalene sulfonic acid), sulfuric acid, and alkanesulfonic acids, such as described in U.S. Pat. No. 2,425,389 to Oxley et al.; U.S. Pat. No. 2,859,241 to Schnizer; and U.S. Pat. No. 4,843,170 to Isshiki et al. The vinyl acetate monomer can also be produced by reacting acetic anhydride with hydrogen in the presence of a catalyst instead of acetaldehyde. This process converts vinyl acetate directly from acetic anhydride and hydrogen without the need to produce ethylidene diacetate. In yet another embodiment, the vinyl acetate monomer can be produced from the reaction of acetaldehyde and a ketene in the presence of a suitable solid catalyst, such as a perfluorosulfonic acid resin or zeolite.
One or more drug compounds are also be dispersed within the core polymer matrix that are capable of prohibiting and/or treating a condition, disease, and/or cosmetic state a patient. The drug compound may be prophylactically, therapeutically, and/or cosmetically active, systemically or locally. Regardless, at least one drug compound within the core is a “macromolecular” compound in the sense that it has a large molecular weight, such as about 0.5 kilodaltons (“kDa”) or more, in some embodiments about 1 kDa or more, in some embodiments from about 5 kDa to about 250 kDa, and in some embodiments, from about 20 kDa to about 200 kDa. Typically, the bioactivity of such compounds depends upon a unique three-dimensional (e.g., folded) structure of the molecule. This three-dimensional molecular structure is substantially maintained by specific non-covalent bonding interactions, such as hydrogen bonding and hydrophobic bonding interactions between atoms (hydrophobicity). The drug compound can be either naturally occurring or man-made by any method known in the art. Typically, it is also desired that the drug compound is stable at high temperatures so that it can be incorporated into the polymer matrix at or near the melting temperature of the hydrophobic polymer employed in the core polymer matrix. For example, the drug compound typically remains stable at temperatures of from about 25° C. to about 120° C., in some embodiments from about 40° C. to about 110° C., in some embodiments from about 40° C. to about 100° C., in some embodiments from about 40° C. to about 80° C., and in some embodiments, from about 50° C. to about 70° C.
Particular examples of suitable macromolecular drug compounds may include, for instance, proteins, peptides, enzymes, antibodies, interferons, interleukins, blood factors, vaccines, nucleotides, lipids, etc., as well as analogues, derivatives, and combinations thereof. Suitable proteins or peptides may include, for instance, adrenocorticotropic hormone, angiotensin, beta-endorphin, bombesin, calcitonin, calcitonin gene relating polypeptide, cholecystokinin-8, colony stimulating factors, desmopressin, endothelin, enkephalin, erythropoietins, gastrins, glucagon, human atrial natriuretic polypeptide, interferons, insulin, growth factors, growth hormones, luteinizing hormone release hormone, melanocyte stimulating hormone, muramyl-dipeptide, neurotensin, oxytocin, parathyroid hormone, peptide T, secretin, somatomedins, somatostatin, thyroid stimulating hormone, thyrotropin releasing hormone, thyrotropin stimulating hormone, vasoactive intestinal polypeptide, vasopressin, etc. Suitable antibodies (e.g., monoclonal antibodies) may include, without limitation, HIV monoclonal antibody 2F5, rituxumab, infliximab, trastuzumab, adalimumab, omalizumab, tositumomab, efalizumab, and cetuximab. Suitable interferons may include interferon alpha-2b, peg interferon alpha-2b, interferon alpha-2b+ribavirin, interferon alpha-2a, pegylated interferon alpha-2a, interferon beta-1a, and interferon beta. Suitable blood factors may include alteplase/tenecteplase and rhesus factor Vila. Suitable interleukins may include interleukin-2. Suitable vaccines may include whole viral particles, recombinant proteins, subunit proteins such as gp41, gp120 and gp140, DNA vaccines, plasmids, bacterial vaccines, polysaccharides such as extracellular capsular polysaccharides, and other vaccine vectors. Likewise, suitable nucleic acids may include RNA- or DNA-based molecules, such as oligonucleotides, aptamers, ribozymes, DNAzymes and small interfering RNAs, such as messenger (mRNA), transfer (tRNA), ribosomal (rRNA), interfering (iRNA), small interfering (siRNA), etc.
The core may also optionally contain one or more excipients if so desired, such as radiocontrast agents, release modifiers, bulking agents, plasticizers, surfactants, crosslinking agents, flow aids, colorizing agents (e.g., chlorophyll, methylene blue, etc.), antioxidants, stabilizers, lubricants, other types of antimicrobial agents, preservatives, etc. to enhance properties and processability. When employed, the optional excipient(s) typically constitute from about 0.01 wt. % to about 20 wt. %, and in some embodiments, from about 0.05 wt. % to about 15 wt. %, and in some embodiments, from about 0.1 wt. % to about 10 wt. % of the core. In one embodiment, for instance, a radiocontrast agent may be employed to help ensure that the device can be detected in an X-ray based imaging technique (e.g., computed tomography, projectional radiography, fluoroscopy, etc.). Examples of such agents include, for instance, barium-based compounds, iodine-based compounds, zirconium-based compounds (e.g., zirconium dioxide), etc. One particular example of such an agent is barium sulfate. Other known antimicrobial agents and/or preservatives may also be employed to help prevent surface growth and attachment of bacteria, such as metal compounds (e.g., silver, copper, or zinc), metal salts, quaternary ammonium compounds, etc.
Regardless of the particular components employed, the core may be formed through a variety of known techniques, such as by hot-melt extrusion, injection molding, solvent casting, dip coating, spray coating, microextrusion, coacervation, etc. In one embodiment, a hot-melt extrusion technique may be employed. Hot-melt extrusion is generally a solvent-free process in which the components of the core (e.g., hydrophobic polymer, drug compound(s), optional excipients, etc.) may be melt blended and optionally shaped in a continuous manufacturing process to enable consistent output quality at high throughput rates. This technique is particularly well suited to various types of hydrophobic polymers, such as olefin copolymers. Namely, such copolymers typically exhibit a relatively high degree of long-chain branching with a broad molecular weight distribution. This combination of traits can lead to shear thinning of the copolymer during the extrusion process, which help facilitates hot-melt extrusion. Furthermore, the polar comonomer units (e.g., vinyl acetate) can serve as an “internal” plasticizer by inhibiting crystallization of the polyethylene chain segments. This may lead to a lower melting point of the olefin copolymer, which improves the overall flexibility of the resulting material and enhances its ability to be formed into devices of a wide variety of shapes and sizes.
During a hot-melt extrusion process, melt blending may occur at a temperature range of from about 40° C. to about 200° C., in some embodiments, from about 60° C. to about 180° C., and in some embodiments, from about 80° C. to about 150° C. to form a polymer composition. Any of a variety of melt blending techniques may generally be employed. For example, the components may be supplied separately or in combination to an extruder that includes at least one screw rotatably mounted and received within a barrel (e.g., cylindrical barrel). The extruder may be a single screw or twin screw extruder. For example, one embodiment of a single screw extruder may contain a housing or barrel and a screw rotatably driven on one end by a suitable drive (typically including a motor and gearbox). If desired, a twin-screw extruder may be employed that contains two separate screws. The configuration of the screw is not particularly critical and it may contain any number and/or orientation of threads and channels as is known in the art. For example, the screw typically contains a thread that forms a generally helical channel radially extending around a core of the screw. A feed section and melt section may be defined along the length of the screw. The feed section is the input portion of the barrel where the olefin copolymer(s) and/or drug compound(s) are added. The melt section is the phase change section in which the copolymer is changed from a solid to a liquid-like state. While there is no precisely defined delineation of these sections when the extruder is manufactured, it is well within the ordinary skill of those in this art to reliably identify the feed section and the melt section in which phase change from solid to liquid is occurring. Although not necessarily required, the extruder may also have a mixing section that is located adjacent to the output end of the barrel and downstream from the melting section. If desired, one or more distributive and/or dispersive mixing elements may be employed within the mixing and/or melting sections of the extruder. Suitable distributive mixers for single screw extruders may include, for instance, Saxon, Dulmage, Cavity Transfer mixers, etc. Likewise, suitable dispersive mixers may include Blister ring, Leroy/Maddock, CRD mixers, etc. As is well known in the art, the mixing may be further improved by using pins in the barrel that create a folding and reorientation of the polymer melt, such as those used in Buss Kneader extruders, Cavity Transfer mixers, and Vortex Intermeshing Pin mixers.
If desired, the ratio of the length (“L”) to diameter (“D”) of the screw may be selected to achieve an optimum balance between throughput and blending of the components. The L/D value may, for instance, range from about 10 to about 50, in some embodiments from about 15 to about 45, and in some embodiments from about 20 to about 40. The length of the screw may, for instance, range from about 0.1 to about 5 meters, in some embodiments from about 0.4 to about 4 meters, and in some embodiments, from about 0.5 to about 2 meters. The diameter of the screw may likewise be from about 5 to about 150 millimeters, in some embodiments from about 10 to about 120 millimeters, and in some embodiments, from about 20 to about 80 millimeters. In addition to the length and diameter, other aspects of the extruder may also be selected to help achieve the desired degree of blending. For example, the speed of the screw may be selected to achieve the desired residence time, shear rate, melt processing temperature, etc. For example, the screw speed may range from about 10 to about 800 revolutions per minute (“rpm”), in some embodiments from about 20 to about 500 rpm, and in some embodiments, from about 30 to about 400 rpm. The apparent shear rate during melt blending may also range from about 100 seconds−1 to about 10,000 seconds−1, in some embodiments from about 500 seconds−1 to about 5000 seconds−1, and in some embodiments, from about 800 seconds−1 to about 1200 seconds−1. The apparent shear rate is equal to 4Q/πR3, where Q is the volumetric flow rate (“m3/s”) of the polymer melt and R is the radius (“m”) of the capillary (e.g., extruder die) through which the melted polymer flows.
Once melt blended together, the resulting polymer composition may be in the form of pellets, sheets, fibers, filaments, etc., which may be shaped into the core using a variety of known shaping techniques, such as injection molding, compression molding, nanomolding, overmolding, blow molding, three-dimensional printing, etc. Injection molding may, for example, occur in two main phases—i.e., an injection phase and holding phase. During the injection phase, a mold cavity is filled with the molten polymer composition. The holding phase is initiated after completion of the injection phase in which the holding pressure is controlled to pack additional material into the cavity and compensate for volumetric shrinkage that occurs during cooling. After the shot has built, it can then be cooled. Once cooling is complete, the molding cycle is completed when the mold opens and the part is ejected, such as with the assistance of ejector pins within the mold. Any suitable injection molding equipment may generally be employed in the present invention. In one embodiment, an injection molding apparatus may be employed that includes a first mold base and a second mold base, which together define a mold cavity having the shape of the core. The molding apparatus includes a resin flow path that extends from an outer exterior surface of the first mold half through a sprue to a mold cavity. The polymer composition may be supplied to the resin flow path using a variety of techniques. For example, the composition may be supplied (e.g., in the form of pellets) to a feed hopper attached to an extruder barrel that contains a rotating screw (not shown). As the screw rotates, the pellets are moved forward and undergo pressure and friction, which generates heat to melt the pellets. A cooling mechanism may also be provided to solidify the resin into the desired shape of the core (e.g., disc, rod, etc.) within the mold cavity. For instance, the mold bases may include one or more cooling lines through which a cooling medium flows to impart the desired mold temperature to the surface of the mold bases for solidifying the molten material. The mold temperature (e.g., temperature of a surface of the mold) may range from about 50° C. to about 120° C., in some embodiments from about 60° C. to about 110° C., and in some embodiments, from about 70° C. to about 90° C.
As indicated above, another suitable technique for forming a core of the desired shape and size is three-dimensional printing. During this process, the polymer composition may be incorporated into a printer cartridge that is readily adapted for use with a printer system. The printer cartridge may, for example, contains a spool or other similar device that carries the polymer composition. When supplied in the form of filaments, for example, the spool may have a generally cylindrical rim about which the filaments are wound. The spool may likewise define a bore or spindle that allows it to be readily mounted to the printer during use. Any of a variety of three-dimensional printer systems can be employed in the present invention. Particularly suitable printer systems are extrusion-based systems, which are often referred to as “fused deposition modeling” systems. For example, the polymer composition may be supplied to a build chamber of a print head that contains a platen and gantry. The platen may move along a vertical z-axis based on signals provided from a computer-operated controller. The gantry is a guide rail system that may be configured to move the print head in a horizontal x-y plane within the build chamber based on signals provided from controller. The print head is supported by the gantry and is configured for printing the build structure on the platen in a layer-by-layer manner, based on signals provided from the controller. For example, the print head may be a dual-tip extrusion head.
As indicated above, the implantable device contains at least one membrane layer that is positioned adjacent to an outer surface of a core. The number of membrane layers may vary depending on the particular configuration of the device, the nature of the drug compound, and the desired release profile. For example, the device may contain only one membrane layer. Referring to
Of course, in other embodiments, the device may contain multiple membrane layers. In the device of
Regardless of the particular configuration employed, the membrane layer(s) generally contain a membrane polymer matrix that contains a hydrophobic polymer, such as described above. The polymer matrix typically constitutes from about 30 wt. % to 100 wt. %, in some embodiments, from about 40 wt. % to about 99 wt. %, and in some embodiments, from about 50 wt. % to about 90 wt. % of a membrane layer. When employing multiple membrane layers, it is typically desired that each membrane layer contains a polymer matrix that includes such a hydrophobic polymer. For example, a first membrane layer may contain a first polymer matrix and a second membrane layer may contain a second polymer matrix. In such embodiments, the first and second polymer matrices each contain a hydrophobic polymer, which may be the same or different. Likewise, the hydrophobic polymer used in the membrane layer may also be the same or different the hydrophobic polymer employed in the core. In one embodiment, for instance, both the core and the membrane layer(s) employ the same hydrophobic polymer (e.g., α-olefin copolymer). In yet other embodiments, the membrane layer(s) may employ a hydrophobic polymer (e.g., α-olefin copolymer) that has a lower melt flow index than a polymer employed in the core. Among other things, this can further help control the release of the drug compound from the device. For example, the ratio of the melt flow index of a hydrophobic polymer employed in the core to the melt flow index of a hydrophobic polymer employed in the membrane layer(s) may be from about 1 to about 20, in some embodiments about 2 to about 15, and in some embodiments, from about 4 to about 12. The melt flow index of the hydrophobic polymer in the membrane layer(s) may, for example, range from about 1 to about 80 g/10 min, in some embodiments from about 2 to about 70 g/10 min, and in some embodiments, from about 5 to about 60 g/10 min, as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms. Examples of suitable ethylene vinyl acetate copolymers that may be employed include those available from Celanese under the designation ATEVA® (e.g., ATEVA® 4030AC or 2861A).
As indicated above, the membrane layer(s) used in the device may optionally contain a macromolecular drug compound, such as described above, which is dispersed within the polymer matrix. The drug compound in the membrane layer(s) may be the same or different than the drug compound employed in the core. Regardless, when such a macromolecular drug compound is employed in a membrane layer, the membrane layer generally contains the drug compound in an amount such that the ratio of the concentration (wt. %) of the drug compound in the core to the concentration (wt. %) of the drug compound in the membrane layer is greater than 1, in some embodiments about 1.5 or more, and in some embodiments, from about 1.8 to about 4. When employed, drug compounds typically constitute only from about 1 wt. % to about 40 wt. %, in some embodiments from about 5 wt. % to about 35 wt. %, and in some embodiments, from about 10 wt. % to about 30 wt. % of a membrane layer. Of course, in other embodiments, the membrane layer is generally free of such macromolecular drug compounds prior to release from the core. When multiple membrane layers are employed, each membrane layer may generally contains the drug compound in an amount such that the ratio of the weight percentage of the drug compound in the core to the weight percentage of the drug compound in the membrane layer is greater than 1, in some embodiments about 1.5 or more, and in some embodiments, from about 1.8 to about 4.
The membrane layer(s) and/or the core may also optionally contain one or more excipients as described above, such as radiocontrast agents, hydrophilic compounds, bulking agents, plasticizers, surfactants, crosslinking agents, flow aids, colorizing agents (e.g., chlorophyll, methylene blue, etc.), antioxidants, stabilizers, lubricants, other types of antimicrobial agents, preservatives, etc. to enhance properties and processability. When employed, the optional excipient(s) typically constitute from about 0.01 wt. % to about 60 wt. %, and in some embodiments, from about 0.05 wt. % to about 50 wt. %, and in some embodiments, from about 0.1 wt. % to about 40 wt. % of a membrane layer.
To help further control the release rate from the implantable device, for example, a hydrophilic compound may also be incorporated into the polymer matrix of the membrane layer(s) that is soluble and/or swellable in water. When employed, the weight ratio of the hydrophobic polymers to the hydrophilic compounds within the membrane polymer matrix may range about 0.25 to about 200, in some embodiments from about 0.4 to about 80, in some embodiments from about 0.8 to about 20, in some embodiments from about 1 to about 16, and in some embodiments, from about 1.2 to about 10. Such hydrophilic compounds may, for example, constitute from about 1 wt. % to about 50 wt. %, in some embodiments from about 2 wt. % to about 40 wt. %, and in some embodiments, from about 5 wt. % to about 30 wt. % of the membrane polymer matrix, while hydrophobic polymers typically constitute from about 50 wt. % to about 99 wt. %, in some embodiments from about 60 wt. % to about 98 wt. %, and in some embodiments, from about 70 wt. % to about 95 wt. % of the membrane polymer matrix. In such embodiments, hydrophilic compounds may likewise constitute from about 1 wt. % to about 50 wt. %, in some embodiments from about 2 wt. % to about 40 wt. %, and in some embodiments, from about 5 wt. % to about 30 wt. % of a membrane layer. Suitable hydrophilic compounds may include, for instance, polymers, non-polymeric materials (e.g., glycerin, sugars, salts, peptides, etc.), etc. Examples of suitable hydrophilic polymers include, for instance, sodium, potassium and calcium alginates, carboxymethylcellulose, agar, gelatin, polyvinyl alcohols, polyalkylene glycols (e.g., polyethylene glycol), collagen, pectin, chitin, chitosan, poly-1-caprolactone, polyvinylpyrrolidone, poly(vinylpyrrolidone-co-vinyl acetate), polysaccharides, hydrophilic polyurethane, polyhydroxyacrylate, dextran, xanthan, hydroxypropyl cellulose, methylcellulose, proteins, ethylene vinyl alcohol copolymers, water-soluble polysilanes and silicones, water-soluble polyurethanes, etc., as well as combinations thereof. Particularly suitable hydrophilic polymers are polyalkylene glycols, such as those having a molecular weight of from about 100 to 500,000 grams per mole, in some embodiments from about 500 to 200,000 grams per mole, and in some embodiments, from about 1,000 to about 100,000 grams per mole. Specific examples of such polyalkylene glycols include, for instance, polyethylene glycols, polypropylene glycols polytetramethylene glycols, polyepichlorohydrins, etc.
One or more nonionic, anionic, and/or amphoteric surfactants may also be employed to help create a uniform dispersion. When employed, such surfactant(s) typically constitute from about 0.05 wt. % to about 8 wt. %, and in some embodiments, from about 0.1 wt. % to about 6 wt. %, and in some embodiments, from about 0.5 wt. % to about 3 wt. % of the core. Nonionic surfactants, which typically have a hydrophobic base (e.g., long chain alkyl group or an alkylated aryl group) and a hydrophilic chain (e.g., chain containing ethoxy and/or propoxy moieties), are particularly suitable. Some suitable nonionic surfactants that may be used include, but are not limited to, ethoxylated alkylphenols, ethoxylated and propoxylated fatty alcohols, polyethylene glycol ethers of methyl glucose, polyethylene glycol ethers of sorbitol, ethylene oxide-propylene oxide block copolymers, ethoxylated esters of fatty (C8-C18) acids, condensation products of ethylene oxide with long chain amines or amides, condensation products of ethylene oxide with alcohols, fatty acid esters, monoglyceride or diglycerides of long chain alcohols, and mixtures thereof. Particularly suitable nonionic surfactants may include ethylene oxide condensates of fatty alcohols, polyoxyethylene ethers of fatty acids, polyoxyethylene sorbitan fatty acid esters, and sorbitan fatty acid esters, etc. The fatty components used to form such emulsifiers may be saturated or unsaturated, substituted or unsubstituted, and may contain from 6 to 22 carbon atoms, in some embodiments from 8 to 18 carbon atoms, and in some embodiments, from 12 to 14 carbon atoms. Sorbitan fatty acid esters (e.g., monoesters, diester, triesters, etc.) that have been modified with polyoxyethylene are one particularly useful group of nonionic surfactants. These materials are typically prepared through the addition of ethylene oxide to a 1,4-sorbitan ester. The addition of polyoxyethylene converts the lipophilic sorbitan ester surfactant to a hydrophilic surfactant that is generally soluble or dispersible in water. Such materials are commercially available under the designation TWEEN® (e.g., TWEEN® 80, or polyethylene (20) sorbitan monooleate).
The membrane layer(s) may be formed using the same or a different technique than used to form the core, such as by hot-melt extrusion, injection molding, solvent casting, dip coating, spray coating, microextrusion, coacervation, etc. In one embodiment, a hot-melt extrusion technique may be employed. The core and membrane layer(s) may also be formed separately or simultaneously. In one embodiment, for instance, the core and membrane layer(s) are separately formed and then combined together using a known bonding technique, such as by stamping, hot sealing, adhesive bonding, etc.
The implantable device of the present invention may be used in a variety of different ways to treat prohibit and/or treat a condition, disease, or cosmetic state in a patient. The device may be implanted subcutaneously, orally, mucosally, etc., using standard techniques. The delivery route may be intrapulmonary, gastroenteral, subcutaneous, intramuscular, or for introduction into the central nervous system, intraperitoneum or for intraorgan delivery. If desired, the device may be sealed within a package (e.g., sterile blister package) prior to use. The materials and manner in which the package is sealed may vary as is known in the art. In one embodiment, for instance, the package may contain a substrate that includes any number of layers desired to achieve the desired level of protective properties, such as 1 or more, in some embodiments from 1 to 4 layers, and in some embodiments, from 1 to 3 layers. Typically, the substrate contains a polymer film, such as those formed from a polyolefin (e.g., ethylene copolymers, propylene copolymers, propylene homopolymers, etc.), polyester (e.g., polyethylene terephthalate, polyethylene naphthalate, polybutylene terephthalate, etc.), vinyl chloride polymer, vinyl chloridine polymer, ionomer, etc., as well as combinations thereof. One or multiple panels of the film may be sealed together (e.g., heat sealed), such as at the peripheral edges, to form a cavity within which the device may be stored. For example, a single film may be folded at one or more points and sealed along its periphery to define the cavity within with the device is located. To use the device, the package may be opened, such as by breaking the seal, and the device may then be removed and implanted into a patient.
The present invention may be better understood with reference to the following examples.
Drug Release: The release of a drug compound (e.g., bromelain) may be determined using an in vitro method. More particularly, implantable device samples may be placed in 150 milliliters of an aqueous sodium azide solution. The solutions are enclosed in UV-protected, 250-ml Duran® flasks. The flasks are then placed into a temperature-controlled water bath and continuously shaken at 100 rpm. A temperature of 37° C. is maintained through the release experiments to mimic in vivo conditions. Samples are taken in regular time intervals by completely exchanging the aqueous sodium azide solution. The concentration of the drug compound in solution is determined via UV/Vis absorption spectroscopy using a Cary 1 split beam instrument. From this data, the amount of the drug compound released per sampling interval (microgram per hour) is calculated and plotted over time (hours). Further, the cumulative release ratio of the drug compound is also calculated as a percentage by dividing the amount of the drug compound released at each sampling interval by the total amount of drug compound initially present, and then multiplying this number by 100. This percentage is then plotted over time (hours).
Four (4) different types of core layers are formed with varying concentrations of a hydrophobic polymer (Ateva® 4030AC) and a macromolecular biologic (bromelain). To form the samples, bromelain powder is initially melt compounded into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 25 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants.
The bromelain and Ateva® 4030AC contents inside the different core layers are given in Table 1.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Three (3) different types of core-membrane implantable devices are formed using a core layer containing 20 wt. % of a hydrophobic polymer and 80 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding bromelain powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants. The membrane layers are formed by melt compounding Ateva® 4030AC and Luviskol® VA64 using a Haake Rheomix 600p in the same manner as described above, except that the resulting discs had a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours. Table 2 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Six (6) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding bromelain powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants. The membrane layers are formed by melt compounding Ateva® 2861A and polyethylene glycol (“PEG”) having a molecular weight of 100,000 grams per mole using a Haake Rheomix 600p in the same manner as described above, except that compounding occurred at a temperature of 170° C. and the resulting discs had a thickness of 0.5 millimeters and a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours. Table 3 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Five (5) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding bromelain powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants. The membrane layers are formed by melt compounding Ateva® 2861A and Luviskol® VA64 using a Haake Rheomix 600p in the same manner as described above, except that compounding occurred at a temperature of 170° C., the temperature used during pressing was 100° C., and the resulting discs had a thickness of 0.5 millimeters and a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours. Table 4 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Two (2) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding bromelain powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants. The membrane layers are formed by melt compounding Ateva® 4030AC, polyethylene glycol (“PEG”) having a molecular weight of 100,000 grams per mole, and bromelain powder using a Haake Rheomix 600p in the same manner as described above, except that the resulting discs had a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours. Table 5 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Three (3) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding bromelain powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the bromelain powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-bromelain sheet using a punching press to create the bromelain containing core layer/monolithic bromelain implants. The membrane layers are formed by melt compounding Ateva® 4030AC and polyethylene glycol (“PEG”) having a molecular weight of 100,000 grams per mole using a Haake Rheomix 600p in the same manner as described above, except that compounding occurred at a temperature of 50° C., the temperature used during pressing was 80° C., and the resulting discs had a thickness of 0.5 millimeters and a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Four (4) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying concentrations of components in the membrane layers. The core layer is formed by melt compounding collagen powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the collagen powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar. To avoid adhesion of the molten EVA film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the EVA blend and the press plates. After cool down, the polyester films are removed. Discs having a diameter of 23 millimeters are stamped out of the EVA-collagen sheet using a punching press to create the collagen containing core layer/monolithic collagen implants. The membrane layers are formed by melt compounding Ateva® 4030AC and Luviskol® VA64 using a Haake Rheomix 600p in the same manner as described above, except that compounding occurred at a temperature of 50° C., the temperature used during pressing was 50° C., and the resulting discs had a thickness of 1.0 millimeters and a diameter of 25 millimeters. To form the core-membrane implants, a solvent bonding technique is employed. That is, a small amount of toluene is applied on the sides of the discs using a paintbrush and then immediately thereafter the sandwiched layers are bonded and pressed together. Pressure is maintained for a period of 24 hours as the toluene is allowed to evaporate. After this time period, the edge of the core layer is sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges are allowed to dry from toluene for a time period of at least 48 hours. Table 7 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
Three (3) different types of core-membrane implantable devices are formed using a core layer containing 40 wt. % of a hydrophobic polymer and 60 wt. % of a biologic in combination with varying with varying concentrations of components in the membrane layers. The core rod is formed by melt compounding bromelain powder into Ateva® 4030AC using a DSM bench top double-screw extruder with conical, intermeshing screws. First, Ateva® 4030AC (1 mm fine powder) is dry blended with bromelain. The blended mixture is then fed into the DSM extruder. The extrusion temperature was 60° C. and the screw speed was 50 rpm. The extruded filament is allowed to cool down to room temperature and then cut into 30 mm long rods. The diameter of the extruded filament was 3.4 mm. The membrane layer is formed by melt compounding Luviskol® VA64 powder into Ateva® 4030AC using a Haake Rheomix 600p. First, the Rheomix 600p chamber is filled with Ateva® 4030AC pellets and compounded for 8 minutes at 50° C. The compounding in the Rheomix 600p is done at 50 rpm using roller-type rotors. After 8 minutes, the Luviskol® VA64 powder is added to the Ateva® 4030AC melt and melt mixing continues for 3 minutes at 50° C. After melt mixing, the blend is taken out of the Rheomix 600p and pressed into 1 mm thick sheets using a thermal press. The temperature during pressing is 50° C., the pressing time is 3 minutes, and the pressure is 100 bar.
To avoid adhesion of the molten Ateva® 4030AC film to the surfaces of the press, a low-adhesion, temperature-tolerant polyester foil (Hostaphan® RNK 23) is placed between the Ateva® 4030AC blend and the press plates. After cool down, the polyester films are removed. To form the core-membrane implants, a temperature bonding technique is employed. That is the membrane layers and the core rods are heated to 55° C. for 30 minutes. A single membrane layer is then attached to a single core rod manually by applying gentle pressure while rolling the specimen for a prolonged period of time. After this, both ends of the cylinders and the seam between the ends of the membrane layer are sealed using a highly concentrated toluene solution of Ateva® 4030AC applied from a plastic pipette. The edges and the seam are allowed to dry from toluene for a time period of at least 48 hours. Table 8 shows the content of the core and membrane layers used in each Example.
Once formed, the samples were tested for their release rate as described above. The results are set forth in
These and other modifications and variations of the present invention may be practiced by those of ordinary skill in the art, without departing from the spirit and scope of the present invention. In addition, it should be understood that aspects of the various embodiments may be interchanged both in whole or in part. Furthermore, those of ordinary skill in the art will appreciate that the foregoing description is by way of example only, and is not intended to limit the invention so further described in such appended claims.
The present application is a continuation of U.S. application Ser. No. 16/416,325 (filed on May 20, 2019), which claims priority to U.S. application Ser. No. 62/675,982 (filed on May 24, 2018), which is incorporated herein in its entirety by reference thereto.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4014335 | Arnold | Mar 1977 | A |
| 4069307 | Higuchi et al. | Jan 1978 | A |
| 4164560 | Folkman et al. | Aug 1979 | A |
| 4357312 | Hsieh et al. | Nov 1982 | A |
| 4391797 | Folkman et al. | Jul 1983 | A |
| 4663147 | DePrince | May 1987 | A |
| 4666704 | Shalati et al. | May 1987 | A |
| 4792448 | Ranade | Dec 1988 | A |
| 4863735 | Kohn et al. | Sep 1989 | A |
| 4883666 | Sabel et al. | Nov 1989 | A |
| 4891225 | Langer et al. | Jan 1990 | A |
| 4898734 | Mathiowitz et al. | Feb 1990 | A |
| 4900556 | Wheatley et al. | Mar 1990 | A |
| 4933185 | Wheatley et al. | Jun 1990 | A |
| 4952406 | Brown et al. | Aug 1990 | A |
| 4957119 | De Nijs | Sep 1990 | A |
| 4989734 | Mode et al. | Feb 1991 | A |
| 5008112 | DePrince et al. | Apr 1991 | A |
| 5088505 | De Nijs | Feb 1992 | A |
| 5100668 | Edelman et al. | Mar 1992 | A |
| 5150718 | De Nijs | Sep 1992 | A |
| 5302397 | Amsden et al. | Apr 1994 | A |
| 5324523 | Zsuga et al. | Jun 1994 | A |
| 5330768 | Park et al. | Jul 1994 | A |
| 5378475 | Smith et al. | Jan 1995 | A |
| 5439688 | Orsolini et al. | Aug 1995 | A |
| 5512293 | Landrau et al. | Apr 1996 | A |
| 5514378 | Mikos et al. | May 1996 | A |
| 5543465 | Bell et al. | Aug 1996 | A |
| 5545409 | Laurencin et al. | Aug 1996 | A |
| 5601835 | Sabel et al. | Feb 1997 | A |
| 5626862 | Brem et al. | May 1997 | A |
| 5626877 | Amsden et al. | May 1997 | A |
| 5686877 | Keller et al. | Nov 1997 | A |
| 5733565 | Moo-Young et al. | Mar 1998 | A |
| 5783567 | Hedley et al. | Jul 1998 | A |
| 5827525 | Liao et al. | Oct 1998 | A |
| 5858388 | Grossman et al. | Jan 1999 | A |
| 5877224 | Brocchini et al. | Mar 1999 | A |
| 5902598 | Chen et al. | May 1999 | A |
| 5916584 | O'Donoghue et al. | Jun 1999 | A |
| 5989581 | Groenewegen | Nov 1999 | A |
| 6001386 | Ashton et al. | Dec 1999 | A |
| 6083534 | Wallach et al. | Jul 2000 | A |
| 6096764 | Bryant et al. | Aug 2000 | A |
| 6117441 | Moo-Young et al. | Sep 2000 | A |
| 6159143 | Lennox | Dec 2000 | A |
| 6217895 | Guo et al. | Apr 2001 | B1 |
| 6248057 | Mavity et al. | Jun 2001 | B1 |
| 6262034 | Mathiowitz et al. | Jul 2001 | B1 |
| 6281015 | Mooney et al. | Aug 2001 | B1 |
| RE37410 | Brem et al. | Oct 2001 | E |
| 6331313 | Wong et al. | Dec 2001 | B1 |
| 6344035 | Chudzik et al. | Feb 2002 | B1 |
| 6375972 | Guo et al. | Apr 2002 | B1 |
| 6423345 | Bernstein et al. | Jul 2002 | B2 |
| 6471993 | Shastri et al. | Oct 2002 | B1 |
| 6565845 | Cherksey et al. | May 2003 | B2 |
| 6565874 | Dunn et al. | May 2003 | B1 |
| 6544546 | Joseph Groenewegen et al. | Jul 2003 | B1 |
| 6689390 | Bernstein et al. | Feb 2004 | B2 |
| 6713081 | Robinson et al. | Mar 2004 | B2 |
| 6719750 | Varner et al. | Apr 2004 | B2 |
| 6730322 | Bernstein et al. | May 2004 | B1 |
| 6767550 | Génin et al. | Jul 2004 | B1 |
| 6918927 | Bates et al. | Jul 2005 | B2 |
| 6964781 | Brubaker | Nov 2005 | B2 |
| 6991808 | Brubaker et al. | Jan 2006 | B2 |
| 7005454 | Brocchini et al. | Feb 2006 | B2 |
| 7052719 | Bernstein et al. | May 2006 | B2 |
| 7097850 | Chappa et al. | Aug 2006 | B2 |
| 7115256 | Allen et al. | Oct 2006 | B1 |
| 7189461 | Rabasco et al. | Mar 2007 | B2 |
| 7195774 | Carvalho et al. | Mar 2007 | B2 |
| 7309689 | Trigg et al. | Dec 2007 | B2 |
| 7442402 | Chudzik et al. | Oct 2008 | B2 |
| 7452866 | Thorn et al. | Nov 2008 | B2 |
| 7531503 | Atala et al. | May 2009 | B2 |
| 7534449 | Saltzman et al. | May 2009 | B2 |
| 7594899 | Pinchuk et al. | Sep 2009 | B2 |
| 7666445 | Siegel et al. | Feb 2010 | B2 |
| 7708711 | Tu et al. | May 2010 | B2 |
| 7736665 | Patel et al. | Jun 2010 | B2 |
| 7763277 | Canham et al. | Jul 2010 | B1 |
| 7803178 | Whirley et al. | Sep 2010 | B2 |
| 7829112 | Ron et al. | Nov 2010 | B2 |
| 7833168 | Taylor et al. | Nov 2010 | B2 |
| 7833545 | Ron et al. | Nov 2010 | B2 |
| 7833548 | Chappa et al. | Nov 2010 | B2 |
| 7838024 | Ron et al. | Nov 2010 | B2 |
| 7871643 | Lizio et al. | Jan 2011 | B2 |
| 7883718 | Ron et al. | Feb 2011 | B2 |
| 7901707 | Allen et al. | Mar 2011 | B2 |
| 7989018 | McNiven et al. | Aug 2011 | B2 |
| 8021680 | Anderson et al. | Sep 2011 | B2 |
| 8039010 | Trogden et al. | Oct 2011 | B2 |
| 8096972 | Varner et al. | Jan 2012 | B2 |
| 8097236 | Aston et al. | Jan 2012 | B2 |
| 8119154 | Huang et al. | Feb 2012 | B2 |
| 8147865 | Huang et al. | Apr 2012 | B2 |
| 8173163 | Kohn et al. | May 2012 | B2 |
| 8182464 | Lee et al. | May 2012 | B2 |
| 8197839 | Martinod et al. | Jun 2012 | B2 |
| 8221778 | Siegel et al. | Jul 2012 | B2 |
| 8232313 | Munn et al. | Jul 2012 | B2 |
| 8236857 | Dill | Aug 2012 | B2 |
| 8257730 | Huang et al. | Sep 2012 | B2 |
| 8263108 | Gibson et al. | Sep 2012 | B2 |
| 8263110 | Huang et al. | Sep 2012 | B2 |
| 8273375 | Lizio et al. | Sep 2012 | B2 |
| 8298565 | Taylor et al. | Oct 2012 | B2 |
| 8298570 | Huang et al. | Oct 2012 | B2 |
| 8333983 | Groenewegen et al. | Dec 2012 | B2 |
| 8348877 | Tu et al. | Jan 2013 | B2 |
| 8399518 | Morkin et al. | Mar 2013 | B2 |
| 8440216 | Huang et al. | May 2013 | B2 |
| 8454582 | deJuan et al. | Jun 2013 | B2 |
| 8465769 | Petereit et al. | Jun 2013 | B2 |
| 8475820 | Kuzma et al. | Jul 2013 | B2 |
| 8481079 | De Graaff et al. | Jul 2013 | B2 |
| 8541028 | Staas et al. | Sep 2013 | B2 |
| 8568766 | Anantharamaiah et al. | Oct 2013 | B2 |
| 8568778 | Lizio et al. | Oct 2013 | B2 |
| 8580735 | Francois et al. | Nov 2013 | B2 |
| 8642089 | Petereit et al. | Feb 2014 | B2 |
| 8647657 | Gibson et al. | Feb 2014 | B2 |
| 8685427 | Li et al. | Apr 2014 | B2 |
| 8697104 | Knezevich et al. | Apr 2014 | B2 |
| 8722037 | Veenstra et al. | May 2014 | B2 |
| 8734849 | Lizio et al. | May 2014 | B2 |
| 8741329 | de Graaff et al. | Jun 2014 | B2 |
| 8747883 | Labib et al. | Jun 2014 | B2 |
| 8753667 | Variano et al. | Jun 2014 | B2 |
| 8765152 | Lizio et al. | Jul 2014 | B2 |
| 8765166 | Kopezynski et al. | Jul 2014 | B2 |
| 8771722 | Huang et al. | Jul 2014 | B2 |
| 8795242 | Hoganson et al. | Aug 2014 | B2 |
| 8795707 | Wolinsky et al. | Aug 2014 | B2 |
| 8808744 | de Graaff et al. | Aug 2014 | B2 |
| 8840920 | Nugara et al. | Sep 2014 | B2 |
| 8852623 | Patel et al. | Oct 2014 | B2 |
| 8858977 | Groenewegen et al. | Oct 2014 | B2 |
| 8858993 | Gold et al. | Oct 2014 | B2 |
| 8871241 | Chou et al. | Oct 2014 | B2 |
| 8889174 | Gibson et al. | Nov 2014 | B1 |
| 8900615 | Groenewegen et al. | Dec 2014 | B2 |
| 8900616 | Belcheva et al. | Dec 2014 | B2 |
| 8911426 | Coppeta et al. | Dec 2014 | B2 |
| 8911427 | Seiler et al. | Dec 2014 | B2 |
| 8962009 | Huang et al. | Feb 2015 | B2 |
| 8962010 | Woolfson et al. | Feb 2015 | B2 |
| 8962011 | Raspagliesi | Feb 2015 | B2 |
| 8980298 | Schwarz | Mar 2015 | B2 |
| 8992979 | Emanuel et al. | Mar 2015 | B2 |
| 9066782 | Tu et al. | Jun 2015 | B2 |
| 9078900 | Kuzma et al. | Jul 2015 | B2 |
| 9107899 | Furst et al. | Aug 2015 | B2 |
| 9132081 | Loxley et al. | Sep 2015 | B2 |
| 9132088 | Sim et al. | Sep 2015 | B2 |
| 9175162 | Pacetti et al. | Nov 2015 | B2 |
| 9296687 | George et al. | Mar 2016 | B2 |
| 9301926 | Indolfi et al. | Apr 2016 | B2 |
| 9327059 | Huang et al. | May 2016 | B2 |
| 9345686 | De Graaff | May 2016 | B2 |
| 9370444 | Cunningham, Jr. | Jun 2016 | B2 |
| 9370558 | Ali et al. | Jun 2016 | B2 |
| 9492400 | Jon et al. | Nov 2016 | B2 |
| 9585912 | Sherman et al. | Mar 2017 | B2 |
| 9668977 | Schattka et al. | Jun 2017 | B2 |
| 9687506 | Sherman et al. | Jun 2017 | B2 |
| 9775815 | Schattka et al. | Oct 2017 | B2 |
| 9782346 | Venkatraman et al. | Oct 2017 | B2 |
| 9789001 | Tu et al. | Oct 2017 | B2 |
| 9808420 | Kopczynski et al. | Nov 2017 | B2 |
| 9821045 | Ali et al. | Nov 2017 | B2 |
| 9844511 | Nollenberger et al. | Dec 2017 | B2 |
| 9872829 | Loxley et al. | Jan 2018 | B2 |
| 9872912 | Chiou et al. | Jan 2018 | B2 |
| 9895318 | Joshi et al. | Feb 2018 | B2 |
| 9896576 | Zhang et al. | Feb 2018 | B2 |
| 9956172 | McGinity et al. | May 2018 | B2 |
| 9987233 | Helliwell et al. | Jun 2018 | B2 |
| 9999595 | Rakic et al. | Jun 2018 | B2 |
| 10010612 | Dadey et al. | Jul 2018 | B2 |
| 10028851 | Dugan et al. | Jul 2018 | B2 |
| 10029034 | Falotico et al. | Jul 2018 | B2 |
| 10058554 | Luk et al. | Aug 2018 | B2 |
| 10098836 | Csaky | Oct 2018 | B2 |
| 10111830 | Patel et al. | Oct 2018 | B2 |
| 10111838 | Joshi et al. | Oct 2018 | B2 |
| 10123971 | Patel et al. | Nov 2018 | B2 |
| 10226419 | Arps et al. | Mar 2019 | B2 |
| 10286197 | Pouliot et al. | May 2019 | B2 |
| 10413504 | de Graaff et al. | Sep 2019 | B2 |
| 10413612 | Goldberg et al. | Sep 2019 | B2 |
| 10434063 | McGinity et al. | Oct 2019 | B2 |
| 10435469 | Goldberg et al. | Oct 2019 | B2 |
| 10449145 | Csaky | Oct 2019 | B2 |
| 10548766 | Cuevas | Feb 2020 | B2 |
| 10568949 | Ali et al. | Feb 2020 | B2 |
| 10596103 | Aarts et al. | Mar 2020 | B2 |
| 10624862 | Wening et al. | Apr 2020 | B2 |
| 10639283 | Haksar et al. | May 2020 | B2 |
| 10653621 | Wu et al. | May 2020 | B2 |
| 10682400 | Ali et al. | Jun 2020 | B2 |
| 10702551 | Stephan | Jul 2020 | B2 |
| 10835604 | Ngwa et al. | Nov 2020 | B2 |
| 10836826 | Goldberg et al. | Nov 2020 | B2 |
| 10869833 | Kopczynski et al. | Dec 2020 | B2 |
| 10874768 | Morgan et al. | Dec 2020 | B2 |
| 10881609 | Csaky | Jan 2021 | B2 |
| 11021539 | Goldberg et al. | Jun 2021 | B2 |
| 20020081556 | Tseng et al. | Jun 2002 | A1 |
| 20030149008 | Sahadevan | Aug 2003 | A1 |
| 20030203000 | Schwarz et al. | Oct 2003 | A1 |
| 20040121014 | Guo et al. | Jun 2004 | A1 |
| 20040224000 | Deghenghi | Nov 2004 | A1 |
| 20050031668 | Patel et al. | Feb 2005 | A1 |
| 20050220895 | Bucalo et al. | Oct 2005 | A1 |
| 20050244462 | Farooq | Nov 2005 | A1 |
| 20060003008 | Gibson et al. | Jan 2006 | A1 |
| 20060089410 | Bucalo et al. | Apr 2006 | A1 |
| 20060141049 | Lyons et al. | Jun 2006 | A1 |
| 20060147437 | Allen et al. | Jul 2006 | A1 |
| 20060160745 | Igari et al. | Jul 2006 | A1 |
| 20060188543 | Feng | Aug 2006 | A1 |
| 20070128294 | Bucalo et al. | Jun 2007 | A1 |
| 20070134332 | Turnell et al. | Jun 2007 | A1 |
| 20070179097 | Furuya et al. | Aug 2007 | A1 |
| 20070231406 | Bucalo et al. | Oct 2007 | A1 |
| 20070248637 | Chappa et al. | Oct 2007 | A1 |
| 20070260203 | Donello et al. | Nov 2007 | A1 |
| 20070275031 | Patel et al. | Nov 2007 | A1 |
| 20080145406 | Asgharian et al. | Jun 2008 | A1 |
| 20080166391 | Gibson et al. | Jul 2008 | A1 |
| 20090011007 | Meier et al. | Jan 2009 | A1 |
| 20090035381 | Stankus et al. | Feb 2009 | A1 |
| 20090092650 | Warren et al. | Apr 2009 | A1 |
| 20090104243 | Utkhede et al. | Apr 2009 | A1 |
| 20090117168 | Keenan | May 2009 | A1 |
| 20090130176 | Bossy-Nobs et al. | May 2009 | A1 |
| 20090142313 | Talling et al. | Jun 2009 | A1 |
| 20090173906 | Park et al. | Jul 2009 | A1 |
| 20090311304 | Borck et al. | Dec 2009 | A1 |
| 20100104619 | De Graaff et al. | Apr 2010 | A1 |
| 20100158799 | Chudzik et al. | Jun 2010 | A1 |
| 20100158980 | Kopczynski et al. | Jun 2010 | A1 |
| 20100203104 | De Graff et al. | Aug 2010 | A1 |
| 20100278725 | Liu et al. | Nov 2010 | A1 |
| 20100285097 | Talling et al. | Nov 2010 | A1 |
| 20100303883 | Pollock et al. | Dec 2010 | A1 |
| 20110038936 | Griswold et al. | Feb 2011 | A1 |
| 20110045076 | Kiser et al. | Feb 2011 | A1 |
| 20110105990 | Silvestrini | May 2011 | A1 |
| 20110230963 | Cuevas | Sep 2011 | A1 |
| 20110280922 | Ron et al. | Nov 2011 | A1 |
| 20120029042 | King | Feb 2012 | A1 |
| 20120078362 | Haffner et al. | Mar 2012 | A1 |
| 20120164193 | Dill | Jun 2012 | A1 |
| 20120207682 | Ashton | Aug 2012 | A1 |
| 20120277852 | Shukia et al. | Nov 2012 | A1 |
| 20130122096 | Shemi et al. | May 2013 | A1 |
| 20130189342 | Patel et al. | Jul 2013 | A1 |
| 20130195951 | Patel et al. | Aug 2013 | A1 |
| 20130202673 | Patel et al. | Aug 2013 | A1 |
| 20130218081 | Roth | Aug 2013 | A1 |
| 20130273137 | Mandell et al. | Oct 2013 | A1 |
| 20130287688 | Jain et al. | Oct 2013 | A1 |
| 20140037746 | Ashton et al. | Feb 2014 | A1 |
| 20140086995 | Ratner et al. | Mar 2014 | A1 |
| 20140088131 | Patel et al. | Mar 2014 | A1 |
| 20140094407 | Ron et al. | Apr 2014 | A1 |
| 20140127228 | Marks et al. | May 2014 | A1 |
| 20140209100 | Kiser et al. | Jul 2014 | A1 |
| 20140212355 | Trollsas et al. | Jul 2014 | A1 |
| 20140234381 | Tao et al. | Aug 2014 | A1 |
| 20140234389 | Shiah et al. | Aug 2014 | A1 |
| 20140271765 | Patel | Sep 2014 | A1 |
| 20140314966 | Fink et al. | Oct 2014 | A1 |
| 20140328884 | Reyes et al. | Nov 2014 | A1 |
| 20140363484 | Koyakutty et al. | Dec 2014 | A1 |
| 20150004213 | Ron | Jan 2015 | A1 |
| 20150140062 | Shiah et al. | May 2015 | A1 |
| 20150190348 | Haksar et al. | Jul 2015 | A1 |
| 20150209488 | Siegel et al. | Jul 2015 | A1 |
| 20150230971 | Wildemeersch | Aug 2015 | A1 |
| 20150297509 | Schwarz | Oct 2015 | A1 |
| 20150306230 | Combs et al. | Oct 2015 | A1 |
| 20150342894 | Anderson | Dec 2015 | A1 |
| 20150366825 | Joshi et al. | Dec 2015 | A1 |
| 20160008399 | Stephan | Jan 2016 | A1 |
| 20160022571 | Schwarz et al. | Jan 2016 | A1 |
| 20160067071 | Jose et al. | Mar 2016 | A1 |
| 20160081933 | Hensel et al. | Mar 2016 | A1 |
| 20160143844 | Carrasquillo et al. | May 2016 | A1 |
| 20160206633 | Barth et al. | Jul 2016 | A1 |
| 20160302965 | Erickson et al. | Oct 2016 | A1 |
| 20170121513 | Zhang et al. | May 2017 | A1 |
| 20170246117 | Helliwell et al. | Aug 2017 | A1 |
| 20180125780 | Grattoni et al. | May 2018 | A1 |
| 20180140556 | Joshi et al. | May 2018 | A1 |
| 20180214507 | Kacker et al. | Aug 2018 | A1 |
| 20180256606 | Petereit et al. | Sep 2018 | A1 |
| 20180280194 | Heitzmann et al. | Oct 2018 | A1 |
| 20180333296 | Heitzmann et al. | Nov 2018 | A1 |
| 20190046434 | Mota Leite Machado Mariz et al. | Feb 2019 | A1 |
| 20190112354 | Forsayeth et al. | Apr 2019 | A1 |
| 20190184145 | Munster et al. | Jun 2019 | A1 |
| 20190307885 | Zugates et al. | Oct 2019 | A1 |
| 20190358167 | Schneider | Nov 2019 | A1 |
| 20200000976 | Jeffery | Jan 2020 | A1 |
| 20200093852 | Nelms et al. | Mar 2020 | A1 |
| 20200113829 | Chang et al. | Apr 2020 | A1 |
| 20200138707 | McGinity et al. | May 2020 | A1 |
| 20200138729 | Schwartz et al. | May 2020 | A1 |
| 20200179374 | Orefice et al. | Jun 2020 | A1 |
| 20200197327 | Wening et al. | Jun 2020 | A1 |
| 20200316159 | Ghatnekar | Oct 2020 | A1 |
| 20210007973 | Patel et al. | Jan 2021 | A1 |
| 20210113664 | Patel et al. | Apr 2021 | A1 |
| 20210177742 | Patel | Jun 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 765149 | Sep 2003 | AU |
| 2176145 | May 1995 | CA |
| 101011345 | Aug 2007 | CN |
| 101385698 | Mar 2009 | CN |
| 103435424 | Mar 2016 | CN |
| 102013011399 | Feb 2014 | DE |
| 0 290 891 | Nov 1988 | EP |
| 2 265 293 | Nov 2015 | EP |
| H 10230148 | Sep 1998 | JP |
| 20210010226 | Jan 2021 | KR |
| WO 2006063242 | Jun 2006 | WO |
| WO 2009129459 | Oct 2009 | WO |
| WO 2010133757 | Nov 2010 | WO |
| WO 2010133761 | Nov 2010 | WO |
| WO 2011116132 | Sep 2011 | WO |
| WO 2013178811 | Dec 2013 | WO |
| WO 2013178812 | Dec 2013 | WO |
| WO 2014160026 | Oct 2014 | WO |
| WO 2016064959 | Apr 2016 | WO |
| WO 2016079204 | May 2016 | WO |
| WO 2016180764 | Nov 2016 | WO |
| WO 2018067882 | Apr 2018 | WO |
| WO 2019213128 | Nov 2019 | WO |
| WO 2020006240 | Jan 2020 | WO |
| WO 2020041500 | Feb 2020 | WO |
| WO 2020198737 | Oct 2020 | WO |
| Entry |
|---|
| Abstract—Almeida et al., “Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hot-melt extrusion,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 77, Issue 2, Feb. 2011, pp. 297-305. |
| Abstract of Almeida, A. et al., “Sustained release from hot-melt extruded matrices based on ethylene vinyl acetate and polyethylene oxide,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, Issue 3, Nov. 2012, pp. 526-533. |
| Agarwal et al., “Injectable implants for the sustained release of protein and peptide drugs,” Drug Discovery Today, vol. 18, Nos. 7/8, Apr. 2013, pp. 337-349. |
| Ahmed et al., “Recent Advances in Polymeric Implants,” AAPS PharmSciTech, (2019) 20: 300, 10 pages. |
| Bix et al, “Elvax as a slow-release delivery agent for a platelet-activating factor receptor agonist and antagonist,” Journal of Neuroscience Methods, 77, 1997, pp. 67-74. |
| Bloch et al., “Nerve Growth Factor- and Neurotrophin-3-Releasing Guidance Channels Promote Regeneration of the Transected Rat Dorsal Root,” Experimental Neurology 172, 2001, pp. 425-432. |
| Daukss et al., “Microscale implantable drug delivery systems: emerging IP strategies,” News & Analysis Biobusiness Briefs, Nature Reviews, Drug Discovery, Nov. 2016, vol. 15, pp. 740-741. |
| Doughty et al., “Short Communication—Neurotrophin-3 promotes cerebellar granulate cell exit from the EGL.” European Journal of Neuroscience, vol. 10, 1998, pp. 3007-3011. |
| Feng et al., “Twin-screw extrusion of sustained-release oral dosage forms and medical implants,” Drug Delivery and Translations Research, 2018, 8, pp. 1694-1713. |
| Jong et al, “Controlled release of plasmid DNA,” Journal of Controlled Release, Release 47, 1997, pp. 123-134. |
| Kimball et al., “A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist vial transvaginal ring delivery system,” Journal of Controlled Release 233, 2016, pp. 19-28. |
| Kuo-Haller et al., “Vaccine delivery by polymeric vehicles in the mouse reproductive tract induce sustained local and systemic immunity,” Mol. Pharm., Oct. 4, 2010, 7(5), pp. 1585-1595. |
| Langer et al., “Polymers for the sustained release of proteins and other macromolecules,” Nature, vol. 263, pp. 797-800. |
| Loxley, Andrew, “Hot Melt-Extrusion in the Production of Intra-vaginal Rings Containing Antiretroviral Drugs,” ANTEC 2010, May 18, 2010, 28 pages. |
| Master Dissertation of Pharm. Kristof Dhaenens entitled “Ethylene Vinyl Acetate as Matrix for Oral Sustained Release Multiple-Unit Dosage Forms Produced via Hot-Melt Extrusion,” 2009-2010, Universiteit Gent, Department of Pharmaceutics, 61 pages. |
| Paper—Stanković et al., “Polymeric formulations for drug release prepared by Hot Melt Extrusion, Application and characterization,” pp. 16-49. |
| Preis et al., “Short Communication—A Single-Step Immunization by Sustained Antigen Release,” Journal of Immunological Methods, 28, 1979, pp. 193-197. |
| Ramgopal et al., “Sustained Release of Complexed and Naked DNA from Polymer Films,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2007, pp. 496-503. |
| Saltzman et al, “Intracranial Delivery of Recombinant Nerve Growth Factor: Release Kinetics and Protein Distribution for Three Delivery Systems,” Pharmaceutical Research, vol. 16, No. 2, 1999, pp. 232-240. |
| Saltzman et al., “Transport rates of proteins in porous materials with known microgeometry,” Biophys. J. (Biophysical Society), vol. 55, Jan. 1989, pp. 163-171. |
| Schneider et al., “Applications of ethylene vinyl acetate copolymers (EVA) in drug delivery systems,” Journal of Controlled Release 262, 2017, pp. 284-295. |
| Shin et al., “Controlled release of triprolidine using ethylene-vinyl acetate membrane and matrix systems,” European Journal of Pharmaceutics and Biopharmaceutics 54, May 5, 2002, pp. 201-206. |
| Supplementary European Search Report for EP 19 80 6736 dated Jan. 20, 2022, 11 pages. |
| Supplementary Search Report for EP 19 80 6504 dated Feb. 15, 2022, 18 pages. |
| International Search Report and Written Opinion for PCT/US2019/033059 dated Jul. 23, 2019, 14 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20230277470 A1 | Sep 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62675982 | May 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16416325 | May 2019 | US |
| Child | 18315605 | US |
